Quantification of Host Cell Protein Impurities Using the Agilent 1290 Infinity II LC Coupled with the 6495B Triple Quadrupole LC/MS System

Significance of the topic

Biotherapeutic proteins produced in host cells can carry low-level impurities known as host cell proteins (HCPs). Even trace amounts of HCPs can affect drug safety, efficacy, and immunogenicity. Regulatory guidelines require sensitive, specific monitoring of individual HCP species. Traditional ELISA methods lack the resolution to identify and quantify specific HCPs, motivating the adoption of advanced LC/MS approaches for detailed impurity profiling.

Objectives and study overview

This application note demonstrates a targeted workflow for absolute quantification of HCPs at sub-parts-per-million levels in a monoclonal antibody (mAb) matrix. Key goals include improving sensitivity, specificity, and throughput by integrating automated sample preparation, high-performance LC separation, and optimized triple quadrupole MS detection.

Methodology and instrumentation used

The workflow consists of automated sample handling and a multiple reaction monitoring (MRM) MS assay:

• AssayMAP Bravo platform for denaturation, reduction, alkylation, and trypsin digestion of mAb samples spiked with standards.
• Agilent 1290 Infinity II LC system with reversed-phase C18 column (charged surface) and a nine-minute gradient for peptide separation.
• Agilent 6495B Triple Quadrupole LC/MS in dynamic MRM mode with automated collision energy optimization via the Agilent Automation tool within Skyline.
• Stable isotope-labeled (SIL) peptides as internal standards and UPS2 protein set for gold-standard comparison.
• Data processing using Skyline and Agilent MassHunter Quantitative Analysis software.

Main results and discussion

Quantitative performance was evaluated for three target peptides representing two spiked UPS2 proteins (SUMO1 and SYHC) and one endogenous CHO HCP (S100-A11). Key findings:

• Excellent linearity across low sub-ppm to >1,000 ppm (R² ≥ 0.9983) for all peptides.
• Sensitivity down to 6.25–12.5 amol/µg (0.13–0.70 ppm LLOQ) with precision (%RSD ≤ 17 %) and accuracy within 80–112 %.
• Retention time reproducibility (%RSD ≤ 0.32 %) over 56 injections.
• Automated MRM method development in Skyline delivered rapid collision energy and retention time optimization without manual intervention.
• Absolute quantification with SIL peptides underestimated spiked protein levels by ~50 % compared to UPS2 protein standards, highlighting the need to account for digestion and recovery efficiency.

Benefits and practical applications

This integrated workflow offers:

• Highly reproducible, high-throughput sample preparation reducing manual handling variability.
• Sensitive detection of low-abundance HCPs in high-background biotherapeutic matrices.
• Automated MRM method creation and optimization to accelerate assay development.
• Scalable quantification strategy suitable for batch-to-batch quality monitoring during bioprocess development and QC release testing.

Future trends and potential applications

Advances in automation, high-resolution MS, and data analysis tools are expected to further enhance HCP profiling capabilities. Integration of isotopically labeled full-length proteins, improved peptide recovery strategies, and machine-learning–driven data interpretation will enable even more accurate, comprehensive impurity assessment. These developments will support tighter control of biomanufacturing processes and accelerate regulatory approval of novel biologics.

Conclusion

The combination of the AssayMAP Bravo platform, Agilent 1290 Infinity II LC, 6495B Triple Quadrupole MS, and Skyline/MassHunter software provides a robust, sensitive, and automated solution for quantifying HCP impurities at sub-ppm levels in biotherapeutic products. This workflow meets regulatory expectations for specificity and reproducibility while enabling rapid assay deployment.

Reference

1. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
2. Host Cell Protein Analysis Using Agilent AssayMAP Bravo and 6545XT AdvanceBio LC/Q-TOF. Agilent Technologies, publication 5991-9300EN.
3. Agilent Triple Quadrupole LC/MS Peptide Quantitation with Skyline. Agilent Technologies, publication 5990-9887EN.
4. Separation of Peptide Standards Using Formic Acid as a Mobile Phase Additive. Agilent Technologies, publication 5991-8597EN.
5. Gerber, S. A. et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA. 2003.